<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00602953</url>
  </required_header>
  <id_info>
    <org_study_id>042007-021</org_study_id>
    <secondary_id>1K23RR02447001</secondary_id>
    <nct_id>NCT00602953</nct_id>
  </id_info>
  <brief_title>Role of Pancreatic Triglyceride Content in Beta-cell Function</brief_title>
  <official_title>Role of Pancreatic Triglyceride Content in Beta-cell Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates if fat accumulates in the pancreas in individuals at risk of developing
      obesity-related diabetes. It also evaluates if the amount of fat in the pancreas can predict
      the residual functional capacity of the pancreas (insulin secretion).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pancreatic and Liver Fat</measure>
    <time_frame>Within 1 month after screening visit.</time_frame>
    <description>Pancreatic and liver triglyceride (fat) content measured by the magnetic resonance spectroscopy (MRS) technique in volunteers with a wide range of body mass index (BMI).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Beta-cell Function; AIRg - Acute Insulin Response to Glucose</measure>
    <time_frame>At screening visit.</time_frame>
    <description>Beta-cell function as measured by frequently sampled intravenous glucose tolerance test (FSIVGTT) in volunteers with a wide range of body mass index (BMI).
AIRg - acute insulin response to glucose. Blood samples were collected at -5, -1, 2, 3, 4, 5, 6, 8, 10, 14, 19, 22, 25, 30, 40, 50, 70, 100, 140, and 180 minutes, where time 0 is when an i.v. bolus of 50% glucose solution (0.3 g/kg) was injected.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin Sensitivity (SI)</measure>
    <time_frame>At screening visit.</time_frame>
    <description>Sensitivity index measured during frequently sampled intravenous glucose tolerance test (FSIVGTT) in volunteers with a wide range of body mass index (BMI).
Blood samples were collected at -5, -1, 2, 3, 4, 5, 6, 8, 10, 14, 19, 22, 25, 30, 40, 50, 70, 100, 140, and 180 minutes, where time 0 is when an i.v. bolus of 50% glucose solution (0.3 g/kg) was injected. Higher numbers indicates better insulin sensitivity Insulin sensitivity was estimated as Matsuda index using formula = 10,000 / (FPG x FPI x Glucosemean0-180 x Insulinmean0-180)0.5, where FPG = fasting plasma glucose and FPI = fasting plasma insulin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disposition Index (DI)</measure>
    <time_frame>At screening visit.</time_frame>
    <description>Disposition index measured during frequently sampled intravenous glucose tolerance test (FSIVGTT) in volunteers with a wide range of body mass index (BMI). Blood samples were collected at -5, -1, 2, 3, 4, 5, 6, 8, 10, 14, 19, 22, 25, 30, 40, 50, 70, 100, 140, and 180 minutes, where time 0 is when an i.v. bolus of 50% glucose solution (0.3 g/kg) was injected. Disposition index (DI) was used to characterize the correlation between β-cell sensitivity and insulin sensitivity and was determined using formula DI = AIRg x SI (from outcomes 2 and 3). Higher numbers indicates a better improvement in beta-cell function.</description>
  </primary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Actual">101</enrollment>
  <condition>Obesity</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <description>Normal weight and normal glucose tolerance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre-diabetes</arm_group_label>
    <description>Impaired fasting glucose of impaired glucose tolerance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Overweight</arm_group_label>
    <description>Overweight or obese volunteers, but with normal fasting and postprandial glucose levels.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Type 2 diabetes</arm_group_label>
    <description>Patients with type 2 diabetes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Type 1 diabetes</arm_group_label>
    <description>Patients with type 1 diabetes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention planned.</intervention_name>
    <description>This is a cross-sectional observational study, no intervention is planned.</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>Pre-diabetes</arm_group_label>
    <arm_group_label>Overweight</arm_group_label>
    <arm_group_label>Type 2 diabetes</arm_group_label>
    <arm_group_label>Type 1 diabetes</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        We enroll adult volunteers of all ethnicities who have no contraindications to the study
        procedures or use medications that interfere with our measurements.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adults without prior history of pancreatic disease (other than diabetes)

        Exclusion Criteria:

          -  use of unapproved medications

          -  contraindications to the MRI procedure

          -  contraindications to frequent blood draws

          -  pregnancy

          -  use of more than 2 alcoholic drinks/day
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ildiko Lingvay, MD, MPH, MSCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2007</study_first_submitted>
  <study_first_submitted_qc>January 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2008</study_first_posted>
  <results_first_submitted>August 17, 2017</results_first_submitted>
  <results_first_submitted_qc>November 29, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 26, 2017</results_first_posted>
  <last_update_submitted>November 29, 2017</last_update_submitted>
  <last_update_submitted_qc>November 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Ildiko Lingvay</investigator_full_name>
    <investigator_title>MD, MPH, MSCS</investigator_title>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Healthy Volunteers</title>
          <description>Normal weight and normal glucose tolerance.
No intervention planned.: This is a cross-sectional observational study, no intervention is planned.</description>
        </group>
        <group group_id="P2">
          <title>Pre-diabetes</title>
          <description>Impaired fasting glucose of impaired glucose tolerance.
No intervention planned.: This is a cross-sectional observational study, no intervention is planned.</description>
        </group>
        <group group_id="P3">
          <title>Overweight</title>
          <description>Overweight or obese volunteers, but with normal fasting and postprandial glucose levels.
No intervention planned.: This is a cross-sectional observational study, no intervention is planned.</description>
        </group>
        <group group_id="P4">
          <title>Type 2 Diabetes</title>
          <description>Patients with type 2 diabetes.
No intervention planned.: This is a cross-sectional observational study, no intervention is planned.</description>
        </group>
        <group group_id="P5">
          <title>Type 1 Diabetes</title>
          <description>Patients with type 1 diabetes.
No intervention planned.: This is a cross-sectional observational study, no intervention is planned.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="47"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="47"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Healthy Volunteers</title>
          <description>Normal weight and normal glucose tolerance.
No intervention planned.: This is a cross-sectional observational study, no intervention is planned.</description>
        </group>
        <group group_id="B2">
          <title>Pre-diabetes</title>
          <description>Impaired fasting glucose of impaired glucose tolerance.
No intervention planned.: This is a cross-sectional observational study, no intervention is planned.</description>
        </group>
        <group group_id="B3">
          <title>Overweight</title>
          <description>Overweight or obese volunteers, but with normal fasting and postprandial glucose levels.
No intervention planned.: This is a cross-sectional observational study, no intervention is planned.</description>
        </group>
        <group group_id="B4">
          <title>Type 2 Diabetes</title>
          <description>Patients with type 2 diabetes.
No intervention planned.: This is a cross-sectional observational study, no intervention is planned.</description>
        </group>
        <group group_id="B5">
          <title>Type 1 Diabetes</title>
          <description>Patients with type 1 diabetes.
No intervention planned.: This is a cross-sectional observational study, no intervention is planned.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="47"/>
            <count group_id="B4" value="13"/>
            <count group_id="B5" value="0"/>
            <count group_id="B6" value="101"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="101"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31" spread="8"/>
                    <measurement group_id="B2" value="41" spread="10"/>
                    <measurement group_id="B3" value="39" spread="9"/>
                    <measurement group_id="B4" value="47" spread="9"/>
                    <measurement group_id="B6" value="40" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B6" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pancreatic and Liver Fat</title>
        <description>Pancreatic and liver triglyceride (fat) content measured by the magnetic resonance spectroscopy (MRS) technique in volunteers with a wide range of body mass index (BMI).</description>
        <time_frame>Within 1 month after screening visit.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Volunteers</title>
            <description>Normal weight and normal glucose tolerance.
No intervention planned.: This is a cross-sectional observational study, no intervention is planned.</description>
          </group>
          <group group_id="O2">
            <title>Pre-diabetes</title>
            <description>Impaired fasting glucose of impaired glucose tolerance.
No intervention planned.: This is a cross-sectional observational study, no intervention is planned.</description>
          </group>
          <group group_id="O3">
            <title>Overweight</title>
            <description>Overweight or obese volunteers, but with normal fasting and postprandial glucose levels.
No intervention planned.: This is a cross-sectional observational study, no intervention is planned.</description>
          </group>
          <group group_id="O4">
            <title>Type 2 Diabetes</title>
            <description>Patients with type 2 diabetes.
No intervention planned.: This is a cross-sectional observational study, no intervention is planned.</description>
          </group>
          <group group_id="O5">
            <title>Type 1 Diabetes</title>
            <description>Patients with type 1 diabetes.
No intervention planned.: This is a cross-sectional observational study, no intervention is planned.</description>
          </group>
        </group_list>
        <measure>
          <title>Pancreatic and Liver Fat</title>
          <description>Pancreatic and liver triglyceride (fat) content measured by the magnetic resonance spectroscopy (MRS) technique in volunteers with a wide range of body mass index (BMI).</description>
          <units>percent</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pancreatic fat MRS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.87" lower_limit="0.2" upper_limit="6.26"/>
                    <measurement group_id="O2" value="6.57" lower_limit="1.90" upper_limit="17.93"/>
                    <measurement group_id="O3" value="3.61" lower_limit="0.79" upper_limit="8.98"/>
                    <measurement group_id="O4" value="5.85" lower_limit="3.43" upper_limit="13.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver fat MRS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96" lower_limit="0.61" upper_limit="1.83"/>
                    <measurement group_id="O2" value="4.09" lower_limit="1.86" upper_limit="12.43"/>
                    <measurement group_id="O3" value="3.33" lower_limit="1.29" upper_limit="6.99"/>
                    <measurement group_id="O4" value="8.76" lower_limit="4.93" upper_limit="21.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Beta-cell Function; AIRg - Acute Insulin Response to Glucose</title>
        <description>Beta-cell function as measured by frequently sampled intravenous glucose tolerance test (FSIVGTT) in volunteers with a wide range of body mass index (BMI).
AIRg - acute insulin response to glucose. Blood samples were collected at -5, -1, 2, 3, 4, 5, 6, 8, 10, 14, 19, 22, 25, 30, 40, 50, 70, 100, 140, and 180 minutes, where time 0 is when an i.v. bolus of 50% glucose solution (0.3 g/kg) was injected.</description>
        <time_frame>At screening visit.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Volunteers</title>
            <description>Normal weight and normal glucose tolerance.
No intervention planned.: This is a cross-sectional observational study, no intervention is planned.</description>
          </group>
          <group group_id="O2">
            <title>Pre-diabetes</title>
            <description>Impaired fasting glucose of impaired glucose tolerance.
No intervention planned.: This is a cross-sectional observational study, no intervention is planned.</description>
          </group>
          <group group_id="O3">
            <title>Overweight</title>
            <description>Overweight or obese volunteers, but with normal fasting and postprandial glucose levels.
No intervention planned.: This is a cross-sectional observational study, no intervention is planned.</description>
          </group>
          <group group_id="O4">
            <title>Type 2 Diabetes</title>
            <description>Patients with type 2 diabetes.
No intervention planned.: This is a cross-sectional observational study, no intervention is planned.</description>
          </group>
          <group group_id="O5">
            <title>Type 1 Diabetes</title>
            <description>Patients with type 1 diabetes.
No intervention planned.: This is a cross-sectional observational study, no intervention is planned.</description>
          </group>
        </group_list>
        <measure>
          <title>Beta-cell Function; AIRg - Acute Insulin Response to Glucose</title>
          <description>Beta-cell function as measured by frequently sampled intravenous glucose tolerance test (FSIVGTT) in volunteers with a wide range of body mass index (BMI).
AIRg - acute insulin response to glucose. Blood samples were collected at -5, -1, 2, 3, 4, 5, 6, 8, 10, 14, 19, 22, 25, 30, 40, 50, 70, 100, 140, and 180 minutes, where time 0 is when an i.v. bolus of 50% glucose solution (0.3 g/kg) was injected.</description>
          <units>microU/mL x min</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="197.55" lower_limit="118.15" upper_limit="237.42"/>
                    <measurement group_id="O2" value="321.09" lower_limit="151.71" upper_limit="446.46"/>
                    <measurement group_id="O3" value="519.33" lower_limit="385.59" upper_limit="927.69"/>
                    <measurement group_id="O4" value="8.9" lower_limit="1.0" upper_limit="56.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Insulin Sensitivity (SI)</title>
        <description>Sensitivity index measured during frequently sampled intravenous glucose tolerance test (FSIVGTT) in volunteers with a wide range of body mass index (BMI).
Blood samples were collected at -5, -1, 2, 3, 4, 5, 6, 8, 10, 14, 19, 22, 25, 30, 40, 50, 70, 100, 140, and 180 minutes, where time 0 is when an i.v. bolus of 50% glucose solution (0.3 g/kg) was injected. Higher numbers indicates better insulin sensitivity Insulin sensitivity was estimated as Matsuda index using formula = 10,000 / (FPG x FPI x Glucosemean0-180 x Insulinmean0-180)0.5, where FPG = fasting plasma glucose and FPI = fasting plasma insulin.</description>
        <time_frame>At screening visit.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Volunteers</title>
            <description>Normal weight and normal glucose tolerance.
No intervention planned.: This is a cross-sectional observational study, no intervention is planned.</description>
          </group>
          <group group_id="O2">
            <title>Pre-diabetes</title>
            <description>Impaired fasting glucose of impaired glucose tolerance.
No intervention planned.: This is a cross-sectional observational study, no intervention is planned.</description>
          </group>
          <group group_id="O3">
            <title>Overweight</title>
            <description>Overweight or obese volunteers, but with normal fasting and postprandial glucose levels.
No intervention planned.: This is a cross-sectional observational study, no intervention is planned.</description>
          </group>
          <group group_id="O4">
            <title>Type 2 Diabetes</title>
            <description>Patients with type 2 diabetes.
No intervention planned.: This is a cross-sectional observational study, no intervention is planned.</description>
          </group>
          <group group_id="O5">
            <title>Type 1 Diabetes</title>
            <description>Patients with type 1 diabetes.
No intervention planned.: This is a cross-sectional observational study, no intervention is planned.</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Sensitivity (SI)</title>
          <description>Sensitivity index measured during frequently sampled intravenous glucose tolerance test (FSIVGTT) in volunteers with a wide range of body mass index (BMI).
Blood samples were collected at -5, -1, 2, 3, 4, 5, 6, 8, 10, 14, 19, 22, 25, 30, 40, 50, 70, 100, 140, and 180 minutes, where time 0 is when an i.v. bolus of 50% glucose solution (0.3 g/kg) was injected. Higher numbers indicates better insulin sensitivity Insulin sensitivity was estimated as Matsuda index using formula = 10,000 / (FPG x FPI x Glucosemean0-180 x Insulinmean0-180)0.5, where FPG = fasting plasma glucose and FPI = fasting plasma insulin.</description>
          <units>min-1 per pU/mL x 10v4</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.48" lower_limit="3.85" upper_limit="7.46"/>
                    <measurement group_id="O2" value="2.28" lower_limit="1.6" upper_limit="4.55"/>
                    <measurement group_id="O3" value="2.29" lower_limit="1.54" upper_limit="2.84"/>
                    <measurement group_id="O4" value="1.55" lower_limit="1.28" upper_limit="3.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Disposition Index (DI)</title>
        <description>Disposition index measured during frequently sampled intravenous glucose tolerance test (FSIVGTT) in volunteers with a wide range of body mass index (BMI). Blood samples were collected at -5, -1, 2, 3, 4, 5, 6, 8, 10, 14, 19, 22, 25, 30, 40, 50, 70, 100, 140, and 180 minutes, where time 0 is when an i.v. bolus of 50% glucose solution (0.3 g/kg) was injected. Disposition index (DI) was used to characterize the correlation between β-cell sensitivity and insulin sensitivity and was determined using formula DI = AIRg x SI (from outcomes 2 and 3). Higher numbers indicates a better improvement in beta-cell function.</description>
        <time_frame>At screening visit.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Volunteers</title>
            <description>Normal weight and normal glucose tolerance.
No intervention planned.: This is a cross-sectional observational study, no intervention is planned.</description>
          </group>
          <group group_id="O2">
            <title>Pre-diabetes</title>
            <description>Impaired fasting glucose of impaired glucose tolerance.
No intervention planned.: This is a cross-sectional observational study, no intervention is planned.</description>
          </group>
          <group group_id="O3">
            <title>Overweight</title>
            <description>Overweight or obese volunteers, but with normal fasting and postprandial glucose levels.
No intervention planned.: This is a cross-sectional observational study, no intervention is planned.</description>
          </group>
          <group group_id="O4">
            <title>Type 2 Diabetes</title>
            <description>Patients with type 2 diabetes.
No intervention planned.: This is a cross-sectional observational study, no intervention is planned.</description>
          </group>
          <group group_id="O5">
            <title>Type 1 Diabetes</title>
            <description>Patients with type 1 diabetes.
No intervention planned.: This is a cross-sectional observational study, no intervention is planned.</description>
          </group>
        </group_list>
        <measure>
          <title>Disposition Index (DI)</title>
          <description>Disposition index measured during frequently sampled intravenous glucose tolerance test (FSIVGTT) in volunteers with a wide range of body mass index (BMI). Blood samples were collected at -5, -1, 2, 3, 4, 5, 6, 8, 10, 14, 19, 22, 25, 30, 40, 50, 70, 100, 140, and 180 minutes, where time 0 is when an i.v. bolus of 50% glucose solution (0.3 g/kg) was injected. Disposition index (DI) was used to characterize the correlation between β-cell sensitivity and insulin sensitivity and was determined using formula DI = AIRg x SI (from outcomes 2 and 3). Higher numbers indicates a better improvement in beta-cell function.</description>
          <units>Number</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1001.8" lower_limit="744.52" upper_limit="1332.1"/>
                    <measurement group_id="O2" value="739.84" lower_limit="478.15" upper_limit="1026.53"/>
                    <measurement group_id="O3" value="1031.26" lower_limit="749.6" upper_limit="1796.35"/>
                    <measurement group_id="O4" value="15.61" lower_limit="4.31" upper_limit="133.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Healthy Volunteers</title>
          <description>Normal weight and normal glucose tolerance.
No intervention planned.: This is a cross-sectional observational study, no intervention is planned.</description>
        </group>
        <group group_id="E2">
          <title>Pre-diabetes</title>
          <description>Impaired fasting glucose of impaired glucose tolerance.
No intervention planned.: This is a cross-sectional observational study, no intervention is planned.</description>
        </group>
        <group group_id="E3">
          <title>Overweight</title>
          <description>Overweight or obese volunteers, but with normal fasting and postprandial glucose levels.
No intervention planned.: This is a cross-sectional observational study, no intervention is planned.</description>
        </group>
        <group group_id="E4">
          <title>Type 2 Diabetes</title>
          <description>Patients with type 2 diabetes.
No intervention planned.: This is a cross-sectional observational study, no intervention is planned.</description>
        </group>
        <group group_id="E5">
          <title>Type 1 Diabetes</title>
          <description>Patients with type 1 diabetes.
No intervention planned.: This is a cross-sectional observational study, no intervention is planned.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. ILDIKO LINGVAY</name_or_title>
      <organization>UT Southwestern Medical Center, Dallas, TX</organization>
      <phone>214-648-2779</phone>
      <email>ildiko.lingvay@utsouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

